

Curriculum Vitae

Surname:	BATH
Forename:	Philip Michael William
Current Position and organisation:	Stroke Association Professor of Stroke Medicine Head, Division of Clinical Neuroscience Honorary Consultant Stroke Physician Nottingham University Hospitals NHS Trust
Address:	City Hospital campus, Hucknall Road, Nottingham NG5 1PB
Tel:	0115 823 1765
Email:	philip.bath@nottingham.ac.uk

Qualifications/Fellowships:			
B.Sc.	University of London	1979	Physiology
M.B., B.S.	University of London	1982	
M.R.C.P. (UK)	Royal College Physicians (UK)	1986	
M.D.	University of London	1991	Rogers Prize
F.R.C.P.	Royal College Physicians (London)	1998	
Dip. Clin. Hypertension	European Society Hypertension	2002	
F.R.C.Path	Royal College Pathologists	2005	Published research
F.E.S.O.	European Stroke Organization	2005	
F.A.H.A.	American Heart Association	2014	
D.Sc.	University of Nottingham	2015	
F.Med.Sci.	Academy Medical Sciences	2016	
F.W.S.O.	World Stroke Organization	2018	
Posts Held:			
Mar 98 continuing			
Professor	Nottingham University		Stroke Medicine
Hon. Consultant	Hucknall Road, Nottingham NG5 1PB		Hypertension
Current research funding:			
1. Van der Worp B, Bath P , Berge E, Ciccone A, Csiba L, de Winter R, Dippel D, Kobayashi A, Korv J, Lees K, Macleod M, Thomalla G, van de Beek D, Borregaard S, Ntaios G, Randall G, Fuchs B. PREvention of Complications to Improve OUTcome in elderly patients with acute Stroke (PRECIOUS). EU Horizon 2020 , 634809. €5,994,000. Awarded January 2015, to commence September 2015, for 5 years. RH4810			
2. Hamdy S, Rothwell J, Bath PM . An exploration of the application of non-invasive cerebellar stimulation in the neurorehabilitation of dysphagia after stroke. MRC , MR/P006183/1. £845,572. 7/7/2017-6/10/2020. RA48DS			
3. Wardlaw J, Bath P , Doubal F, Dennis M, England T, Sprigg N, Cvorov V, Werring D, Hassan A, Montgomery A. LACunar Intervention (LACI) Trial: Assessment of safety and efficacy of cilostazol and isosorbide mononitrate to prevent recurrent lacunar stroke and progression of cerebral small vessel disease. British Heart Foundation , CS/15/5/31475. £747,598. 1/11/17-31/10/20. RB48XA			
4. Wardlaw JM, Markus HS, O'Brien JT, Doubal F, Quinn TJ, Touz RM, O'Sullivan M, Williams S, Robinson TG, Tyrell P, Bath PM , Sprigg N, McManus RJ, Werring DJ, Rudd A, Haig E. Rates, Risks and Routes to Reduce Vascular Dementia (R4VaD). Stroke Association , £1,279,476.			
5. Majid A, Lawrence CB, Redgrave J, Ince PG, Kennerley AJ, Cousens L, Buchan AM, Bath PM . MICA: Efficacy and safety evaluation of AZD1236 (Matrix metalloproteinase 9 & 12 inhibitor) in experimental stroke. MRC , MR/R005923/1. £721K. 20/11/2017-18/5/2021. RA48EQ			
6. England T, Bath PM , Dineen R, O'Sullivan S, Bell R, Sprigg N, Werring D, Dawson J, Hausenloy D, Montgomery A, Webb J, Gordon A, Yellon D. Remote Ischaemic Conditioning After Stroke 3 (RECAST-3): A multicentre randomised controlled trial. NIHR EME , NIHR128240. £1,658,613. 4/2020-12/2023			
7. Bath PM , Chen X, Garibaldi J, Montgomery A, Quinn T, Sprigg N, Woodhouse L. Assessment of modern machine learning methods and conventional statistical regression techniques in diagnosis and prediction of outcome after acute stroke using big data. British Heart Foundation , PG/19/69/34636. £145,079. 5/2020-2022.			
8. Sprigg N, Bath PM , Roberts I, Hepburn T, Montgomery A, Salman R A-S, Roffe C, Werring			

D, England T, Coats, T, James M, Rick C, Robinson TG, Dineen R, Desborough M, Gard T. Tranexamic acid for hyper acute spontaneous intracerebral haemorrhage TICH-3. **NIHR HTA**, NIHR129917, £4,464,044. 1/5/21-30/4/28.

9. **Bath PM**, Gordon A, Jaki T, Ball J, Rick C, Montgomery A, Juszczak E, Logan P, Lim WS, Royal S, Gage H, Guthrie B, Lasserson D, Howard R, Glover M, Leighton P, Passmore P, Hewitt J, Shenkin S, Quinlan P, Godfrey M. Prophylaxis Treatment of COVID in care homes trial (PROTECT) - Set up and maintenance. **NIHR XP**, NIHR133443. £1,726,187. 1/1/21-31/12/22.
10. Roffe C, **Bath P**, Warusevitane A, Smith C, Dixit A, Sprigg N, Helliwell B, Phillips N, Sim J, Jowett S, Ogollah R. The Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial: a single-blind, randomized controlled trial of metoclopramide for the prevention of pneumonia in patients with dysphagia after an acute stroke. **NIHR HTA**, NIHR130689. £2,201,286. 1/5/21-30/4/25.

Recent Publications:

1. **Bath PMW**, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, Marttila R, Olsson J-E, O'Neill D, Ringelstein B, van der Sande J-J, Turpie AGG, for the tardis Investigators. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. **Lancet** 2001;358:702-10. [Chief Investigator]
2. Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): a randomised controlled trial. **Lancet** 2004;363:439-45. [MRC grant applicant, Trial Steering Committee member, UK National coordinator]
3. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, **Bath P**, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; the PROfESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent strokes. **NEJM** 2008;359(12):1238-51. Aug 27 (epub). [Member, Trial Steering Committee; Co-chair, Substudies Committee; Member Publications Committee]
4. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, **Bath P**, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; the PROfESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. **NEJM** 2008;359(12):1225-37. Aug 27 (epub). [Member, Trial Steering Committee; Co-chair, Substudies Committee; Member Publications Committee]
5. Diener H-C, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Palesch Y, Martin RH, **Bath P**, De Keyser J, Donnan GA, Estol C, Teal P, Roberts R, for the Prevention Regimen for Effectively Avoiding Second Strokes (PROfESS) Study Group. Effects of aspirin plus extended-release dipyridamole and telmisartan on disability of recurrent stroke and cognitive function in patients with ischemic stroke: Results from the randomised Prevention Regimen for Effectively Avoiding Second Strokes (PROfESS) Trial. **Lancet Neurology** 2008;7(10):875-84. Aug 29 epub [Member, Trial Steering Committee; Co-chair, Substudies Committee; Member Publications Committee]
6. Sandset EC, **Bath PM**, Boysen G, Jatuzis D, K  rv J, L  ders S, Murray GD, Richter PS, Roine RO, Ter  nt A, Thijs V, Berge E; SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo controlled, double-blind trial. **Lancet** 2011;377:741-50. Epub 26 Feb 2011. [Member, Trial Steering Committee; Advisor, analysis of primary outcome]
7. Whiteley WN, Adams HP Jr, **Bath PM**, Berge E, Sandset PM, Dennis M, Murray GD, Wong KS, Sandercock PA. Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. **Lancet Neurology** 2013 Jun;12(6):539-45. doi: 10.1016/S1474-4422(13)70079-6. Epub 2013 May 2. PMID: 23642343.
8. **Bath PM**, Woodhouse L, Scutt P, Krishnan K, Wardlaw JM, Bereczki D, Sprigg N, Berge E, Beridze M, Caso V, Chen C, Christensen H, Collins R, El Etribi A, Laska AC, Lees KR, Ozturk S, Phillips S, Pocock S, de Silva HA, Szatmari S, Utton S; for ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for

- management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. **Lancet**. 2015 Feb 14;385(9968):617-28. [Chief Investigator]
9. Kalladka D, Sinden J, Pollock K, Haig C, McLean J, Smith W, McConnachie A, Santosh C, **Bath PM**, Dunn L, Muir KW. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. **Lancet** 2016 Aug 20;388(10046):787-96. doi: 10.1016/S0140-6736(16)30513-X. Epub 2016 Aug 3. PMID: 27497862 [Initially Chief Investigator, latterly Chair DMC]
 10. **Bath PM**, Woodhouse LJ, Appleton JP, Beridze M, Christensen H, Dineen RA, Duley L, England TJ, Flaherty K, Havard D, Heptinstall S, James M, Krishnan K, Markus HS, Montgomery AA, Pocock SJ, Randall M, Ranta A, Robinson TG, Scutt P, Venables GS, Sprigg N; TARDIS Investigators. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. **Lancet** 2017 Dec 20. [Chief Investigator]
 11. Sprigg N, Flaherty K, Appleton JP, Al-Shahi Salman R, Bereczki D, Beridze M, Christensen H, Ciccone A, Collins R, Czlonkowska A, Dineen RA, Duley L, Egea-Guerrero JJ, England TJ, Krishnan K, Laska AC, Law ZK, Ozturk S, Pocock SJ, Roberts I, Robinson TG, Roffe C, Seiffge D, Scutt P, Thanabalan J, Werring D, Whynes D, **Bath PM**; TICH-2 Investigators. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. **Lancet** 2018 May 26;391(10135):2107-2115. [Deputy Chief Investigator]
 12. Dziewas R, Stellato R, van der Tweel I, Walther E, Werner CJ, Braun T, Citerio G, Jandl M, Friedrichs M, Nötzel K, Vosko MR, Mistry S, Hamdy S, McGowan S, Warnecke T, Zwittag P, **Bath PM**, on behalf of the PHAST-TRAC Investigators. PHaryngeal electrical STimulation for early decannulation in TRACheotomised stroke patients with neurogenic dysphagia (PHAST-TRAC): a prospective randomised single-blinded trial. **Lancet Neurology** 2018; 17; 849-59. [Chair, Steering Committee, Senior Author]
 13. **Bath PM**, Scutt P, Anderson CS, Ankolekar S, Appleton JP, Berge E, Cala L, Dixon M, England TJ, Godolphin PJ, Havard D, Haywood L, Hepburn T, Krishnan K, Mair G, Montgomery AA, Muir K, Phillips SJ, Pocock S, Potter J, Price CI, Randall M, Robinson TG, Roffe C, Rothwell PM, Sandset EC, Sanossian N, Saver JL, Shone A, Siriwardena AN, Wardlaw JM, Woodhouse LJ, Venables G, Sprigg N; for the RIGHT-2 Investigators. Pre-hospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): a randomised, sham-controlled, blinded, phase III, superiority ambulance-based trial. **Lancet** 2019 Feb 6. [Chief Investigator]
 14. Anderson CS, Huang Y, Lindley RI, Chen X, Arima H, Chen G, Li Q, Billot L, Delcourt C, **Bath PM**, Broderick JP, Demchuk AM, Donnan GA, Durham AC, Lavados PM, Lee TH, Levi C, Martins SO, Olavarria VV, Pandian JD, Parsons MW, Pontes-Neto OM, Ricci S, Sato S, Sharma VK, Silva F, Song L, Thang NH, Wardlaw JM, Wang JG, Wang X, Woodward M, Chalmers J, Robinson TG; ENCHANTED Investigators and Coordinators. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. **Lancet** 2019 Mar 2;393(10174):877-888.
 15. van der Worp HB, Macleod MR, **Bath PM**, Bathula R, Christensen H, Colam B, Cordonnier C, Demotes-Mainard J, Durand-Zaleski I, Gluud C, Jakobsen JC, Kallmünzer B, Kollmar R, Krieger DW, Lees KR, Michalski D, Molina C, Montaner J, Roine RO, Petersson J, Perry R, Sprigg N, Staykov D, Szabo I, Vanhooren G, Wardlaw JM, Winkel P, Schwab S; EuroHYP-1 investigators. Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trial. **Eur Stroke J**. 2019 Sep;4(3):254-262.
 16. Muir KW, Bulters D, Willmot M, Sprigg N, Dixit A, Ward N, Tyrrell P, Majid A, Dunn L, **Bath P**, Howell J, Stroemer P, Pollock K, Sinden J. Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2). **J Neurol Neurosurg Psychiatry**. 2020 Apr;91(4):396-401.
 17. **Bath PM**, Woodhouse LJ, Suntrup-Krueger S, Likar R, Koestenberger M, Warusevitane A, Herzog J, Schuttler M, Ragab S, Everton L, Ledl C, Walther E, Saltuari L, Pucks-Faes E, Bocksrucker C, Vosko M, de Broux J, Haase CG, Raginis-Zborowska A, Mistry S, Hamdy S, Dziewas R; for PHADER Investigators. Pharyngeal electrical stimulation for neurogenic dysphagia following stroke, traumatic brain injury or other causes: Main results from the PHADER cohort study. **EClinicalMedicine**. 2020 Nov 10;28:100608. [Chief Investigator]